Company intelligence / Profile preview

Hepregen

Medford, Massachusetts, United Statesbiospace.com ↗

Ownership: Private
Development stage: Commercial

Overview

Hepregen developed the HepatoPac® microliver platform—a high-fidelity in vitro human liver model used by pharmaceutical companies to improve predictivity of drug metabolism and toxicity. The technology was commercialized and adopted by over twenty pharma partners before acquisition. No clinical results as it does not develop therapeutics directly.

Therapeutic areas: GastroenterologyOther
Modalities: Device (in vitro model)Platform technology (bioengineered tissue models)
Industry: Non-Drug Biotech

Partnerships

Over twenty pharmaceutical companies using the HepatoPac technology

Beyond the preview

Go deeper on Hepregen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepregen.

Explore the full profile